Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.

被引：7

作者：

Tannir, Nizar M.

Signoretti, Sabina

Choueiri, Toni K.

McDermott, David F.

Motzer, Robert J.

George, Saby

Powles, Thomas

Donskov, Frede

Tykodi, Scott S.

Pal, Sumanta K.

Gupta, Saurabh

Lee, Chung-Wei

McHenry, M. Brent

Rini, Brian I.

机构：

[1] UT MD Anderson Canc Ctr, Houston, TX USA

[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[5] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Roswell Pk Canc Inst, Buffalo, NY USA

[8] Queen Mary Univ London, Barts Canc Ctr, London, England

[9] Aarhus Univ Hosp, Aarhus, Denmark

[10] Univ Washington, Seattle, WA 98195 USA

[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[12] City Hope Natl Med Ctr, Duarte, CA USA

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.352

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

352

引用

页数：3

共 50 条

[31] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Benjamin Duy Tran
Jing Li
Neang Ly
Raffaella Faggioni
Lorin Roskos
Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
[32] Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N plus I) or sunitinib (SUN) in the CheckMate 214 trial.
Carril-Ajuria, Lucia
Motzer, Robert J.
Tannir, Nizar M.
McDermott, David F.
Hammers, Hans J.
Plimack, Elizabeth R.
Donskov, Frede
Rini, Brian I.
Jiang, Ruiyun
Lee, Chung-Wei
Desilva, Heshani
Albiges, Laurence
Roussy, Gustave
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
George, Daniel J.
Spigel, David R.
Gordan, Lucio N.
Kochuparambil, Samith T.
Molina, Ana M.
Yorio, Jeff
Kalebasty, Arash Rezazadeh
McKean, Heidi
Tchekmedyian, Nishan
Tykodi, Scott S.
Zhang, Joshua
Askelson, Margarita
Johansen, Jennifer L.
Hutson, Thomas E.
BMJ OPEN, 2022, 12 (09):
[34] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Tran, Benjamin Duy
Li, Jing
Ly, Neang
Faggioni, Raffaella
Roskos, Lorin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
[35] CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
Escudier, B.
Tannir, N. M.
McDermott, D. F.
Frontera, O. A.
Melichar, B.
Plimack, E. R.
Barthelemy, P.
George, S.
Neiman, V.
Porta, C.
Choueiri, T. K.
Powles, T.
Donskov, F.
Salman, P.
Kollmannsberger, C. K.
Rini, B.
Mekan, S.
McHenry, M. B.
Hammers, H. J.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2017, 28
[36] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019)
Cella, D.
Grunwald, V
Escudier, B.
LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
[37] Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
Motzer, Robert J.
Choueiri, Toni K.
Powles, Thomas
Burotto, Mauricio
Bourlon, Maria Teresa
Hsieh, James J.
Maruzzo, Marco
Shah, Amishi Yogesh
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Porta, Camillo
Goh, Jeffrey C.
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Gupta, Saurabh
Apolo, Andrea B.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[38] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
[39] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
Choueiri, T. K.
Powles, T.
Burotto, M.
Bourlon, M. T.
Zurawski, B.
Oyervides Juarez, V. M.
Hsieh, J. J.
Basso, U.
Shah, A. Y.
Suarez, C.
Hamzaj, A.
Barrios, C. H.
Richardet, M.
Pook, D.
Tomita, Y.
Escudier, B.
Zhang, J.
Simsek, B.
Apolo, A. B.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
[40] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial
Motzer, Robert J.
Powles, Thomas
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria T.
Shah, Amishi Y.
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher M.
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Choueiri, Toni K.
LANCET ONCOLOGY, 2022, 23 (07): : 888 - 898

← 1 2 3 4 5 →